
Fluor Corporation wins US$7.5B share of LNG Canada Phase 2 contract
Full notice to proceed follows LNG Canada's Sept. 28 investment decision; the venture will add two liquefaction trains and a storage tank.

The Sept. 25 finding addresses environmental effects; operating-licence changes and inspections remain before the Pennsylvania unit can resume power.

Full notice to proceed follows LNG Canada's Sept. 28 investment decision; the venture will add two liquefaction trains and a storage tank.

IMC Holdings retains liabilities under a C$9.4M cap subject to mutual adjustment; direct subsidiary debts are excluded from that cap.
LNG Canada will manage construction under the commercial agreements, with work expected to start in early 2027.
The package includes 12 months of stability data from a new manufacturer after two manufacturing-related FDA letters.

The partners plan an October 2026 study start and an end-2027 finish before deciding whether to fund Australian and US processing plants.

Federal support of up to C$36.5M backs demonstration work while a pending licence could permit up to about 30,000 tonnes of lithium carbonate a year.

Exascale reported US$2.7M cash at June 30 and said its Aug. 27 merger gave it access to about US$11.8M in net cash proceeds.

ECG-MR is cleared to flag possible valve disease in at-risk patients 65 and older, while Tempus's Sept. 28 release gave no rollout date.
Final Nakalakwana assays accompany a 291-square-kilometre gravity survey over the Thole-Copper Snake anomaly in Botswana.
CEO Matt Cole says SATA supplied 85 per cent of capital raised; cash stood at US$248.8 million on Sept. 25.
The Sept. 29 announcement assigns the other US$500M to five Samsung affiliates but does not break down their commitments or name a Helix project.
The cannabis banking platform expects SHFS to keep its Nasdaq ticker and round fractional holdings up when split-adjusted trading begins Sept. 30.
The three-year ceiling includes options; DLH did not disclose the funded base period or update its US$408.5M June 30 backlog.
The 18-month HHS award covers all three Xacta modules plus integration, training and migration services.
Hanwa and JOGMEC would take 15% at closing, while NextSource targets a second-half 2027 ramp-up for the plant's first phase.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The proposed subscription would leave Goldgroup with about US$91 million in cash before costs and other commitments.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
HUTCHMED says the application covers MET-driven lung cancer after EGFR inhibitor treatment, supported by a 338-patient Phase 3 trial.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The preliminary proxy advances the proposed quantum-security deal toward a shareholder vote, with closing still targeted for the fourth quarter.
Plurilock holders would receive C$0.084 in cash and 0.0763 QeM shares for each share if the arrangement closes.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Most of the award remains unfunded as Amprius targets 12 million cells a year from a converted U.S. line by early 2028.

UCAM plans a £1.3M warrant exercise, Power Metal will add £600K, and its Fermi interest is set to rise to 45 per cent.

The first Cape Station block is due for contractual commercial operation by Oct. 1, while two more blocks target Jan. 1, 2027.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The perpetual, royalty-free agreement covers two brands, while a Texas launch still requires final state licensure and regulatory approval.

Blöte starts Oct. 1 as Canopy seeks German medical cannabis growth; its June quarter international cannabis revenue was C$9.6M.

The Sept. 25 charter amendment doubles common-share capacity and raises the cannabis landlord’s preferred-share ceiling without a shareholder vote.

Its Texas subsidiary would pay PsyLabs the milestones for the first drug candidate; the binding terms lapse without a definitive agreement by Nov. 30.